Latest Conference Articles

November 11th 2023, 3:30pm

International Kidney Cancer Symposium

Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.

November 11th 2023, 4:03am

International Kidney Cancer Symposium

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

November 11th 2023, 12:08am

International Kidney Cancer Symposium

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

November 10th 2023, 11:51pm

International Kidney Cancer Symposium

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

November 10th 2023, 11:35pm

International Kidney Cancer Symposium

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

November 10th 2023, 11:30pm

International Kidney Cancer Symposium

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

November 10th 2023, 9:45pm

PER® Chemotherapy Foundation Symposium (CFS)

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

November 10th 2023, 9:20pm

PER® Chemotherapy Foundation Symposium (CFS)

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

November 10th 2023, 9:11pm

PER® Chemotherapy Foundation Symposium (CFS)

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

November 10th 2023, 9:05pm

PER® Chemotherapy Foundation Symposium (CFS)

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

November 10th 2023, 8:32pm

PER® Chemotherapy Foundation Symposium (CFS)

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

November 10th 2023, 8:10pm

PER® Chemotherapy Foundation Symposium (CFS)

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

November 10th 2023, 7:11pm

International Kidney Cancer Symposium

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

November 10th 2023, 3:40pm

PER® Chemotherapy Foundation Symposium (CFS)

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

November 10th 2023, 2:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

November 9th 2023, 10:20pm

PER® Chemotherapy Foundation Symposium (CFS)

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

November 9th 2023, 10:05pm

Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.

November 9th 2023, 9:55pm

PER® Chemotherapy Foundation Symposium (CFS)

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

November 9th 2023, 9:47pm

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

November 9th 2023, 2:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.